(Q38297888)

1 September 2017

1 reference

title

Lung cancer in 2014: optimizing lung cancer treatment approaches (English)

1 reference

1 September 2017

1 reference

1

Rafael Rosell

1 reference

1 September 2017

Niki Karachaliou

2

1 reference

PubMed ID

25533943

1 September 2017

language of work or name

English

0 references

publication date

23 December 2014

1 reference

Nature Reviews Clinical Oncology

1 September 2017

1 reference

1 September 2017

12

1 reference

1 September 2017

2

1 reference

1 September 2017

75-76

1 reference

Genetics and biomarkers in personalisation of lung cancer treatment

1 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.225

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.225

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.225

MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.225

[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.225

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.225

Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.225

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.225

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.225

10.1038/NRCLINONC.2014.225

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25533943